Literature DB >> 18456681

Communicating the benefits and harms of treatments.

A K Akobeng1.   

Abstract

Although various measures can be used to describe the benefits and harms of treatments, not all of these clearly show the benefits or otherwise of treatments in a clinically useful way. Relative risk and relative risk reduction are commonly used to describe the results of studies, but they are of limited clinical usefulness as they do not take baseline risks into account and tend to exaggerate the results of studies. Absolute risk measures such as the number needed to treat (NNT) and the number needed to harm (NNH) allow risk to be expressed in a much more clinically relevant way. The absolute risk measures reflect baseline risk and more accurately indicate the magnitude of the treatment effect. However, because they vary according to the baseline risk of the population, they are of limited generalisability, and the published NNT of a treatment in one population cannot be directly applied to another population with a different baseline risk. There are, however, a number of simple methods which can allow us to estimate NNTs or NNHs for our own patients based on published data. The benefits of a treatment (expressed as the NNT) and the harms of the treatment (expressed as the NNH) can be combined into a single ratio called the likelihood of being helped or harmed (LHH). LHH can be adjusted for individual patients by taking account of their own values and unique circumstances.

Entities:  

Mesh:

Year:  2008        PMID: 18456681     DOI: 10.1136/adc.2008.137083

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  13 in total

1.  Authors' Reply to Tsivgoulis et al.: "Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A likelihood to Achieve No Evidence of Disease Activity or Harm Analysis".

Authors:  Dimitrios Papadopoulos; Dimos-Dimitrios D Mitsikostas
Journal:  CNS Drugs       Date:  2019-03       Impact factor: 5.749

Review 2.  Recombinant human follicle-stimulating hormone produces more oocytes with a lower total dose per cycle in assisted reproductive technologies compared with highly purified human menopausal gonadotrophin: a meta-analysis.

Authors:  Philippe Lehert; Joan C Schertz; Diego Ezcurra
Journal:  Reprod Biol Endocrinol       Date:  2010-09-16       Impact factor: 5.211

Review 3.  Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis.

Authors:  Sonia Butalia; Alexander A Leung; William A Ghali; Doreen M Rabi
Journal:  Cardiovasc Diabetol       Date:  2011-04-01       Impact factor: 9.951

4.  Surveying the medical literature: five notable articles in general internal medicine from 2008 and 2009.

Authors:  Alexander A Leung; William A Ghali
Journal:  Open Med       Date:  2010-10-05

Review 5.  What zinc supplementation does and does not achieve in diarrhea prevention: a systematic review and meta-analysis.

Authors:  Archana B Patel; Manju Mamtani; Neetu Badhoniya; Hemant Kulkarni
Journal:  BMC Infect Dis       Date:  2011-05-12       Impact factor: 3.090

6.  Longitudinal numbers-needed-to-treat (NNT) for achieving various levels of analgesic response and improvement with etoricoxib, naproxen, and placebo in ankylosing spondylitis.

Authors:  Paul M Peloso; Arnold Gammaitoni; Steven S Smugar; Hongwei Wang; Andrew R Moore
Journal:  BMC Musculoskelet Disord       Date:  2011-07-18       Impact factor: 2.362

Review 7.  Clinical pregnancy following GnRH agonist administration in the luteal phase of fresh or frozen assisted reproductive technology (ART) cycles: Systematic review and meta-analysis.

Authors:  Le Thi Minh Chau; Duong Khue Tu; Philippe Lehert; Do Van Dung; Le Quang Thanh; Vo Minh Tuan
Journal:  Eur J Obstet Gynecol Reprod Biol X       Date:  2019-05-13

8.  Enhancing communication about paediatric medicines: lessons from a qualitative study of parents' experiences of their child's suspected adverse drug reaction.

Authors:  Janine Arnott; Hannah Hesselgreaves; Anthony J Nunn; Matthew Peak; Munir Pirmohamed; Rosalind L Smyth; Mark A Turner; Bridget Young
Journal:  PLoS One       Date:  2012-10-10       Impact factor: 3.240

Review 9.  Recombinant human follicle-stimulating hormone (r-hFSH) plus recombinant luteinizing hormone versus r-hFSH alone for ovarian stimulation during assisted reproductive technology: systematic review and meta-analysis.

Authors:  Philippe Lehert; Efstratios M Kolibianakis; Christos A Venetis; Joan Schertz; Helen Saunders; Pablo Arriagada; Samuel Copt; Basil Tarlatzis
Journal:  Reprod Biol Endocrinol       Date:  2014-02-20       Impact factor: 5.211

Review 10.  Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence.

Authors:  Mark Hudson; Marcus Schuchmann
Journal:  Eur J Gastroenterol Hepatol       Date:  2019-04       Impact factor: 2.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.